Last reviewed · How we verify

Propofol-based total intravenous anesthesia

The Cleveland Clinic · Phase 3 active Small molecule

Propofol acts as a non-selective GABA_A receptor agonist, enhancing the inhibitory effects of GABA to induce sedation and anesthesia.

Propofol acts as a non-selective GABA_A receptor agonist, enhancing the inhibitory effects of GABA to induce sedation and anesthesia. Used for General anesthesia for surgical procedures, Procedural sedation.

At a glance

Generic namePropofol-based total intravenous anesthesia
Also known asPropofol
SponsorThe Cleveland Clinic
Drug classGABA_A receptor agonist
TargetGABA_A receptor
ModalitySmall molecule
Therapeutic areaAnesthesiology
PhasePhase 3

Mechanism of action

Propofol binds to the GABA_A receptor, increasing the frequency of chloride channel opening and leading to hyperpolarization of neurons, which results in sedation and anesthesia. This mechanism is thought to be responsible for its anesthetic effects, although the exact mechanisms are not fully understood.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: